Hypothesis

Age‑related decline in gut epithelial mitochondrial function releases mitochondrial DNA (mtDNA) into the intestinal lumen and circulation, where it acts as a damage‑associated molecular pattern (DAMP) that activates the cGAS‑STING pathway in brain microglia, driving neuroinflammation independently of classic LPS or SCFA mechanisms.

Rationale

• The gut‑brain axis in aging is a bidirectional loop where dysbiosis, barrier leak, and microglial activation reinforce each other [1] [2].
• Current models emphasize microbial metabolites (CML, LPS, SCFAs) and cytokine signaling (CNTF/JAK/STAT3) as the main routes to microglial activation [1].
• However, aged gut epithelium shows accumulated mitochondrial dysfunction, increased ROS, and mtDNA damage [3](https://www.nad.com/news/gut-bacteria-drive-age-related-immune-changes-in-the-brain). Extracellular mtDNA is a potent DAMP that engages cytosolic cGAS, producing cGAMP and activating STING‑TBK1‑IRF3 signaling, leading to type‑I IFN production and inflammasome priming [4](https://www.frontiersin.org/journals/cellular-neuroscience/articles/10.3389/fncel.2022.944526/full).
• If gut‑derived mtDNA reaches the brain via circulation or vagal afferents, it could directly stimulate microglia, bypassing the need for peripheral cytokine surges.

Novel Mechanistic Insight

We propose that mitochondrial stress in enterocytes triggers the release of mtDNA‑containing extracellular vesicles or naked mtDNA that traverses a compromised barrier, enters the bloodstream, and crosses the blood‑brain barrier via receptor‑mediated transport or passive diffusion in leaky regions. Once in the brain parenchyma, mtDNA is sensed by microglial cGAS, igniting a STING‑dependent interferon response that synergizes with low‑level LPS to produce a hyper‑reactive microglial phenotype. This creates a feed‑forward loop: microglial IFN‑α/β further impairs gut epithelial mitochondrial function via STAT1‑mediated transcriptional repression of PGC‑1α, worsening mtDNA release.

Testable Predictions

1. Elevated gut‑derived mtDNA in aged serum and brain – Quantitative PCR for mtDNA will be higher in portal blood, systemic circulation, and hippocampal tissue of 24‑month mice versus 3‑month controls.
2. cGAS‑STING dependence – Gut‑specific overexpression of mitochondrial transcription factor A (TFAM) to preserve mtDNA integrity, or pharmacological inhibition of cGAS (e.g., RU.521) or STING (e.g., H‑151), will reduce hippocampal IFN‑β, microglial Iba1 activation, and improve spatial memory in aged mice.
3. Microglial mtDNA sensing – Bone‑marrow chimeras where microglia lack cGAS (Cgas^fl/fl × Cx3cr1‑CreER) will resist neuroinflammatory changes despite gut mtDNA elevation, whereas wild‑type microglia transplanted into Cgas‑deficient hosts will regain susceptibility.
4. Rescue via mitochondrial protection – Chronic treatment with the mitochondria‑targeted antioxidant MitoQ or NAD^+ booster NR will lower gut epithelial mtDNA release, diminish circulating mtDNA, and attenuate neuroinflammation.

Experimental Design (outline)

• Animal groups: Young (3 mo), aged (24 mo), aged + gut‑specific TFAM overexpression, aged + cGAS inhibitor, aged + MitoQ, aged + microglial‑cGAS KO.
• Measurements: (a) mtDNA copy number in feces, portal plasma, serum, hippocampus (qPCR); (b) barrier integrity (FITC‑dextran assay); (c) microglial activation (Iba1, CD68, p‑TBK1, IFN‑β immunostaining); (d) behavior (Morris water maze, novel object recognition).
• Controls: Sham‑treated aged mice, vehicle‑treated inhibitor groups, and littermate controls for genetic manipulations.

Falsifiability

If aged mice show no increase in gut‑derived mtDNA, or if blocking cGAS‑STING in microglia fails to reduce neuroinflammation and cognitive decline despite confirmed gut mitochondrial damage, the hypothesis would be refuted. Conversely, demonstration that gut mtDNA elevation precedes and predicts microglial activation, and that its interception rescues cognition, would support the model.

Implications

Reframing the gut‑brain axis to prioritize epithelial mitochondrial health offers a dual‑target strategy: preserving gut mtDNA integrity (via mito‑protective nutrients) and blocking neuronal cGAS‑STING signaling. Such combinatorial intervention could break the self‑amplifying inflammaging loop more effectively than targeting single pathways like LPS or SCFAs alone.